Key result
Varenicline was associated with a 72% increased risk of serious adverse cardiovascular events compared with placebo (OR 1.72) among tobacco users.
Why the study?
Does varenicline increase the risk of serious adverse cardiovascular events compared with placebo among tobacco users?
Meta-Analysis (n=8,216)
Double-blind
Does varenicline increase the risk of serious adverse cardiovascular events compared with placebo among tobacco users?
Effect estimate: OR 1.72 (95% CI 1.09-2.71)
Absolute Event Rate: 1.06% vs 0.82%
Varenicline use in tobacco users is associated with a significantly increased risk of serious adverse cardiovascular events compared to placebo, raising important safety concerns that must be weighed against the benefits of smoking cessation.
No takes yet. Share an insight, caveat, or question.
Warrants caution prescribing varenicline to tobacco users; confirms elevated serious cardiovascular risk versus placebo.
Singh et al. (2011) conducted a meta-analysis in Tobacco use (n=8,216). Varenicline vs. Placebo was evaluated on Any ischemic or arrhythmic adverse cardiovascular event (OR 1.72, 95% CI 1.09-2.71). Varenicline was associated with a 72% increased risk of serious adverse cardiovascular events compared with placebo (OR 1.72) among tobacco users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: